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The antidiabetic potentials of methanol extract (ME) of aerial parts of Phyllanthus niruri L 
(Euphorbiaceae) was evaluated in normal and alloxan diabetic rats. The results showed that ME 
significantly (P<0.05) reduced fasting blood sugar in a dose-related manner and suppressed the 
postprandial rise in blood glucose after a heavy glucose meal in normoglycaemic rats. Chronic oral 
administration of ME caused a significant (P<0.05) dose-related reduction in blood glucose levels as 
well as total cholesterol and triglycerides levels in diabetic and normoglycaemic rats. Sub-chronic 
toxicity study showed that ME-treated rats had significant (P<0.05) reductions in haemoglobin (Hb) 
levels, red blood cell (RBC) and white blood cell (WBC) counts followed by a gradual rise which did not, 
however, attain basal levels; however, there was a progressive rise in the WBC of ME-treated diabetic 
rats. Also ME-treated and control rats had increases in weight throughout the study. Histological 
studies showed that ME-treated diabetic rats had the tissue architecture of their pancreas restored as 
against the control groups where there was evidence of necrosis. The acute toxicity and lethality test of 
ME in mice gave an oral LD50 of 471.2 mg/kg. Results suggest that extract of aerial parts of P. niruri has 
great potentials as anti-diabetic remedy. 
 





Diabetes mellitus (DM) is a metabolic disorder charac-
terized by hyperglycemia due to defective insulin action, 
insulin secretion or both. Several medicinal plants are 
used in the management of DM (Verspohl, 2002; Akah 
et al., 2002; De Sousa et al., 2004; Colca, 2006). One of 
such plants is Phyllanthus niruri L (Euphorbiaceae), an 
annual and field weed that is widespread in temperate 
and tropical climates (Iizuka et al., 2006). P. niruri is a 
small erect annual herb growing up to 30 - 40 cm in 
height and indigenous to the Amazon rainforest and 
other tropical areas, including South East Asia, Southern 
India and China (Girach et al., 1994). The morphology of 
the plant has been described (Bagalkotkar et al., 2006). 
It is popularly used in Asia, Africa and South America 
(Mellinger et al., 2005) as a stomachic, aperitive, anti-
hyperglycemic, antispasmodic, anti-hepatotoxic, anti-
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management of diabetes, constipation, fever including 
malaria, jaundice, hepatitis B, dysentery, gonorrhea, 
syphilis, tuberculosis, cough, influenza, diarrhea, vagi-
nitis, tumors and kidney stones (Syamasundar et al., 
1985; Olive-Bever, 1986; Chopra et al., 1986; Unander 
et al., 1995; Paranjape, 2001; Lin et al., 2003). Studies 
on extracts from various parts of the plant have revealed 
the antioxidant (Tasaduq et al., 2003) and nitric oxide 
scavenging (Jagetia and Baliga, 2004), antimalarial 
(antiplasmodial) (Tona et al., 1999; Tona et al., 2001; 
Cimanga et al., 2004; Tona et al., 2004; Subeki et al., 
2005; Mustofa et al., 2007), antihyperuricemic 
(Murugaiyah and Chan, 2006), antinociceptive/analgesic 
(Santos et al., 1994; Santos et al., 1995), diuretic, hypo-
tensive, hypoglycaemic (Ramakrishnan et al., 1982), 
hepatoprotective (Syamasundar et al., 1985; Chatterjee 
and Sil, 2006; Bhattacharjee and Sil, 2006; Chatterjee et 
al., 2006; Sarkar and Sil., 2007; Bhattacharjee and Sil, 
2007; Manjrekar et al., 2008), hepatocurative (Tasaduq 
et al., 2003), hypolipemic (Khanna et al., 2002), nemati-





(Iizuka et al., 2007), nephrolithiatic (Kieley et al., 2008), 
HIV-1 reverse transcriptase inhibitory (Ogata et al., 
1992), HIV replication inhibitory (Naik and Juvekar, 
2003), HIV/RRE binding inhibitory (Qian-Cutrone et al., 
1996), urolithiatic (Campos and Schor, 1999; Freitas et 
al., 2002; Barros et al., 2003; Nishiura et al., 2004; Micali 
et al., 2006; Barros et al., 2006) and vasorelaxant (Iizuka 
et al., 2006) activities.  
Phytochemical studies have led to the isolation of 
several constituents some of which have also been 
shown to be pharmacologically active. These include the 
alkaloids- 4-methoxy-securinine (Phyllanthine) and 4-
methoxy-nor-securinine (Mulchandani and Hassarajani, 
1984), arabinogalactan which stimulates superoxide 
anion production (Mellinger et al., 2005; Mellinger et al., 
2008), ellagic acid, brevifolin carboxylic acid and ethyl 
brevifolin carboxylate with aldose reductase inhibitory 
effect (Shimizu et al., 1989), 1-O-galloyl-6-O-luteoyl-
alpha-d-glucose with anti-babesial and antiplasmodial 
activities, beta-glucogallin, quercetin 3-O-beta-d-gluco-
pyranosyl-(2-1)-O-beta-d-xylopyranoside, beta sitosterol, 
gallic acid (Subeki et al., 2005), the lignans- phyllanthin, 
hypophyllanthin, phyltetralin with antihyperuricemic 
(Murugaiyah and Chan, 2006) and antihepatotoxic 
effects (Syamasundar et al., 1985), cubebin dimethyl 
ether, urinatetralin (Elfahmi et al., 2006), niranthin 
(Murugaiyah and Chan, 2007), methyl brevifolincar-
boxylate with vasorelaxant (Iizuka et al., 2006) and 
platelet aggregation inhibitory (Iizuka et al., 2007) 
effects, niruriside with HIV/RRE binding inhibitory effect 
(Qian-Cutrone et al., 1996), the prenylated flavanones- 
8-(3-Methyl-but-2-enyl)-2-phenylchroman-4-one and 2-
(4-hydroxyphenyl)-8-(3-methyl-but-2-enyl)-chroman-4-
one with nematicidal activity (Shakil et al., 2008), tria-
contanal and tricontanol with antihepatotoxic effect 
(Syamasundar et al., 1985) and xylans (Mellinger et al., 
2005). 
In continuation of the search for more potent anti-dia-
betic remedies from medicinal plants, we evaluated the 
antidiabetic potentials of P. niruri, a herb popularly used 
in eastern Nigeria for management of diabetes. Although 
the hypoglycaemic activity (Ramakrishnan et al., 1982) 
has been reported, experimental evaluation of the anti-
diabetic potential is yet to be documented. This study 
evaluated the effect of daily oral administration of extract 
of the aerial parts of the plant on glycaemic control in 
normal and diabetic rats as well as indices of the 
diabetic disease such as lipid profile. The effect of the 
extract on the inte-grity of damaged pancreatic tissue 
was also studied. 
 
 




Adult albino rats (100-200 g) and mice (15-27 g) of either sex bred 
in the laboratory animal facility of the Department of Pharmacology   




and Toxicology, University of Nigeria,  Nsukka  were  used  for  the 
study. The animals were kept in steel cages within the facility and 
allowed free access to water and standard livestock pellets. All 
animal experiments were conducted in compliance with the 
National Institute of Health Guide for Care and Use of Laboratory 
Animals (Pub No. 85-23, revised 1985). On transfer to the re-
search area, animals were allowed a 2 week acclimatization period 
before commencement of the experiments. 
 
 
Preparation of extract 
 
Fresh whole plant of P. niruri was collected from Orba town, Enugu 
State Nigeria in August, 2005. The plant was identified and 
authenticated by Mr. A. Ozioko of the International Centre for 
Ethnomedicine and Drug Development (InterCEDD), Nsukka, 
Enugu State. The roots were cut off and discarded, and the aerial 
parts sun-dried for 4 days and milled to coarse powder with an 
electric blender. The powdered plant material (2.4 kg) was 
subjected to continuous extraction in a soxhlet using methanol. 
The extract was concentrated in a rotary evaporator at 40 - 50°C 
under reduced pressure to obtain 288 g of the methanol extract 
(ME; 12% w/w). Phytochemical analysis of ME for identification of 
constituents using procedures described by Trease and Evans 
(1983) and Harborne (1998) gave positive reactions for alkaloids, 




Acute toxicity and lethality (LD50) tests of ME 
 
The acute toxicity and lethality (LD50) of ME in mice (n = 13) was 
estimated using the method described by Lorke (1983). The study 
was carried out in two stages. In stage one, mice (n = 3) received 
oral administration of 10, 100, or 1000 mg/kg of ME (suspended in 
20% Tween 80) and were observed for 24 h for number of deaths. 
At the end of 24 h, only the 1000 mg/kg dose caused death in 
treated mice. Consequently, a fresh batch of mice (n = 1) received 
140, 225, 370 and 600 mg/kg of ME in the second stage of the test 
and were observed for 24 h for deaths. Death occurred only in the 
600 mg/kg dose group. The LD50 was calculated as the geometric 
mean of the highest non-lethal dose (370 mg/kg) and the lowest 
lethal dose (600 mg/kg) (Lorke, 1983). 
 
 
Solvent-guided fractionation of ME and bioactivity-guided 
studies  
 
The methanol extract (ME; 198 g) was subjected to solvent-guided 
fractionation in a silica gel (60-120 mesh size) column succes-
sively eluted with n-hexane, ethylacetate and methanol (100%) in 
order of increasing polarity. The fractions obtained were concen-
trated using rotary evaporator at 40-50°C under reduced pressure 
to afford the n-hexane fraction (HF; 0.09 g; 0.045% w/w), ethyla-
cetate fraction (EF; 37.4 g; 18.9% w/w) and methanol fraction (MF; 
158 g; 79.8% w/w). HF was not tested further because of its very 
low yield. The ME, EF and MF were subjected to biological activity-
guided studies using hypoglycaemic effect in alloxan-induced 
diabetic rats as activity-guide.  
 
 
Hypoglycaemic activity test  
 
The hypoglycaemic effect of the extract (ME) and its solvent 
fractions (EF and MF) was studied in alloxan-induced diabetic rats. 
The animals were fasted for 8 h but allowed free access to water. 
At the end of the fasting period, the basal fasting blood glucose 
(FBG)   levels   of   the  rats  were  determined  using  One  touch®  




glucometer kit (Lifescan, Johnson and Johnson Company, 
Milipitas, CA). Subsequently, diabetes was induced by single 
intraperitoneal injection of alloxan mono-hydrate (70 mg/kg) (Aruna 
et al., 1999) and normal feeding maintained thereafter. Five days 
later, blood was drawn from each rat by tail snipping and the blood 
glucose level measured to establish diabetes. Animals with blood 
glucose level 225 mg/dl were considered diabetic and used for 
the study. The diabetic animals were randomly divided into eight 
groups (n = 5) and received oral administration of ME (200 and 
400 mg/kg), MF (200 and 400 mg/kg), EF (200 and 400 mg/kg), 
20% v/v Tween 80 (5 ml/kg) and glibenclamide (0.2 mg/kg) 
respectively. Extract and fractions were suspended in Tween 80 
(20% v/v). Blood glucose was measured before (0 h) and at 0.5, 1, 
2 and 4 h after treat-ment. The results showed that ME exhibited 
greater hypoglycemic effect than the fractions. Consequently, ME 
was subjected to further studies without fractionation.  
 
 
Effect of ME on normoglycaemic rats 
 
Animals fasted overnight were randomly divided into four groups (n 
= 5) and received oral administration of ME (200 and 400 mg/kg), 
glibenclamide (0.2 mg/kg) and 20% v/v Tween 80 (5 ml/kg) 
respectively. The blood glucose level of each animal was mea-




Oral glucose tolerance test 
 
Animals fasted for 16 h but with free access to water were random-
ly divided into four groups (n = 5) and received oral administration 
of ME (200 and 400 mg/kg), glibenclamide (0.2 mg/kg) and 20% 
v/v Tween 80 (5 ml/kg) respectively. Ninety minutes later, the rats 
were fed with glucose (4 g/kg). The blood glucose level of animals 
in each group was measured before (0) and at 30, 60, 90, 120, 
150 and 180 min after glucose load.  
 
 
Anti-diabetic activity test 
 
The anti-diabetic effect of ME was studied by evaluating the effect 
of its chronic administration on the blood glucose level of alloxan-
induced diabetic rats. The basal fasting blood glucose (FBG) of 
rats was determined and diabetes induced as described above. 
Twenty diabetic rats with glucose level 225 mg/dl were selected 
and used for the study. Rats were fasted for 8 h but allowed free 
access to water. They were randomly divided into four groups (n = 
5). Groups I and II received 200 or 400 mg/kg of ME while groups 
III and IV were diabetic controls and received glibenclamide (0.2 
mg/kg) or 20% v/v Tween 80 (5 ml/kg) respectively. Groups V and 
VI were non-diabetic controls and received ME (200 mg/kg) or 
20% v/v Tween 80 (5 ml/kg). The treatments were administered 
orally to the animals once daily for 28 days. Blood glucose level 
was measured as earlier described before (pretreatment) and on 
days 14 and 28 after commencement of treatment. The body 
weight of each animal was also measured on these days.  
 
 
Determination of effect of ME on lipid profile of diabetic rats 
 
The effect of ME on the lipid profile of treated diabetic rats was 
studied by monitoring the cholesterol and triglyceride levels. Blood 
samples were collected by ocular puncture, transferred into test-
tubes and centrifuged at 3000 rpm for 5 min. The serum was 
collected and the total cholesterol and triglyceride levels of each 





method (Muller et al., 1977) using reagent kits. Lipid levels of 
diabetic animals were measured before (basal) and after the 
induction of diabetes (pre-treatment) as well as on days 14 and 28 
after commencement of treatment. The cholesterol and triglyceride 
levels were determined using commercially available reagent kits 
(QCA, South Africa) following the manufacturer’s instructions. The 
absorbance of each sample containing the reaction mixtures with 
or without serum was read at 540 nm in a UV spectrophotometer 
(UV-2102 PC Spectrophotometer, UNICO®, USA). Total choles-
terol or triglyceride was calculated using the formula: Total choles-
terol (mg/dl) = SAO.D/STO.D × 200, where SAO.D = optical density of 
test sample and STO.D = optical density of standard.  
 
 
Determination of effect of ME on haemoglobin and cell counts 
of diabetic rats 
 
The effect of chronic administration of ME on haemoglobin (Hb) 
and cell counts [white blood cells (WBC) and red blood cells 
(RBC)] of diabetic rats was also determined. Blood samples were 
collected by ocular puncture using haematocrit tubes, transferred 
into EDTA-containing test-tubes and placed in a haematology 
analyzer (Abacus Junior®, Budapest- Hungary) for determination of 
the parameters. Measurements were taken before (basal) and 
after the induction of diabetes (pre-treatment) as well as on days 
14 and 28 after commencement of treatment.  
 
 
Histological studies on the pancreas of ME-treated diabetic 
rats 
 
The effect of ME on tissue architecture of the pancreas of treated 
diabetic rats was evaluated by histological studies of tissue 
sections obtained from the animals. On day 28 of the experiment, 
one animal was randomly selected from the different groups and 
sacrificed by over-dose of chloroform anaesthesia. The whole 
pancreas from each animal was removed and placed in 10% 
formalin in normal saline for histological studies. The isolated 
organ was placed in an automatic tissue processor (Lecia®, Japan) 
for 24 h. After 24 h, the tissues were solidified in molten wax and 
sectioned using automatic tissue sectioner (Sorvall TC-2®; Sorvall 
Inc. Ivan). The tissue sections were then fixed on slides with hae-
matoxylin and eosin. The stained slides were fixed with mountant 






Data was analyzed using one way ANOVA and the results ex-
pressed as mean ± SEM. The results were further subjected to 
LSD post hoc test for multiple comparisons and differences 





Acute toxicity and lethality (LD50) test 
 
The acute toxicity testing of the ME in mice gave an oral 
LD50 of 471.2 mg/kg. 
 
 
Hypoglycaemic effect of ME and fractions 
 
The extract (ME) and fractions significantly (P<0.05) re- 
duced blood glucose level to varying extents  in  diabetic 








Blood glucose level (mg/dl) 
Pre-treatment 0.5 h 1 h 2 h 4 h 
ME 200 359.6 ± 61.1 312.4 ± 58.8 
(13.13) 
293.4 ± 76.0 
(18.41) 
239.0 ± 74.2a 
(33.54) 
223.2 ± 70.6a 
(37.93) 
  400 403.4 ± 57.5 374.2 ± 45.4 
(7.24) 
316.2 ± 52.7 
(21.62) 
268.4 ± 31.0b 
(33.47) 
222.8 ± 28.0a,b 
(44.77) 
EF 200 315.2 ± 20.8 285.6 ± 5.1 
(9.39) 
260.2 ± 24.4b 
(17.44) 
275.6 ± 12.5 
(12.56) 
280.0 ± 7.3 
(11.17) 
  400 353.8 ± 49.2 348.8 ± 48.1 
(1.41) 
329.6 ± 34.7 
(6.84) 
295.8 ± 21.4 
(16.39) 
293.0 ± 20.6 
(17.18) 
MF   200 333.6 ± 17.8 304.0 ± 12.3 
(8.87) 
296.6 ± 11.7 
(11.09) 
278.8 ± 10.5b 
(16.42) 
252.8 ± 13.4a,b 
(24.22) 
  400 285.6 ± 4.2 281.6 ± 2.8 
(1.40) 
273.4 ± 5.5 
(4.27) 
270.2 ± 3.3b 
(5.39) 
261.2 ± 7.8a,b 
(8.54) 
Glibenclamide 0.2 303.0 ± 13.4 256.6 ± 27.0a 
(15.31) 
209.6 ± 31.9a,b 
(30.83) 
193.8 ± 32.2a,b 
(36.04) 
186.4 ± 29.9a,b 
(38.48) 
Control - 366.8 ± 41.2 378.6 ± 58.9 356.8 ± 42.9 356.8 ± 44.4 360.4 ± 43.3 
 
n = 5; a,bP< 0.05 compared to Control and pre-treatment values respectively (ANOVA; LSD post hoc); ME = methanol extract; EF = 
ethyl acetate fraction; MF = methanol fraction. 









Fasting Blood Glucose level (mg/dl) 
Pre-treatment 0.5 h 1 h 2 h 4 h 
ME 200 75.6 ± 2.33 61.4 ± 2.6a,b 
(18.78) 
50.4 ± 3.4a,b 
(33.33) 
50.8 ± 2.82a,b 
(32.80) 
55.4 ± 2.66a,b 
(26.72) 
  400 74.8 ± 3.2 56.0 ± 2.17a,b 
(25.13) 
40.4 ± 1.02a,b 
(45.99) 
45.4 ± 2.56a,b 
(39.30) 
47.6 ± 2.37a,b 
(36.36) 
Glibenclamide 0.2 83.8 ± 7.3 72.0 ± 6.27 
(14.08) 
54.2 ± 4.8a,b 
(35.32) 
48.8 ± 2.82a,b 
(41.77) 
55.4 ± 2.66a,b 
(33.89) 
Control - 80.4 ± 5.39 79.4 ± 5.42 78.2 ± 6.37 79.2 ± 5.34 78.0 ± 5.38 
 
n = 5; a,bP<0.05 compared to Control and pre-treatment values respectively (ANOVA; LSD post hoc); ME = methanol 
extract. 





rats. The hypoglycaemic effect was non-dose-related 




Effect of ME on blood glucose level of 
normoglycaemic rats 
 
The ME caused a significant (P<0.05) dose-related re-
duction in the FBG of normoglycaemic rats. Maximum 
reduction occurred within 1 h post treatment (Table 2). 
Effect of ME on oral glucose tolerance in rats 
 
Following oral administration of glucose meal, post-
prandial blood glucose levels of the control rats rose by 
80% to a peak at 60 min. Pre-treatment with ME (200 
and 400 mg/kg) suppressed the rise in blood glucose 
level by 73.93 and 12.72%, respectively. ME evoked a 
significant (P<0.05) and progressive dose-dependent 
decrease in blood glucose level up to 180 min. At this 
time, the blood glucose level of ME-treated rats 
remained remarkably  below  basal  levels  compared  to  








Blood Glucose level (mg/dl) 
0 min 30 min 60 min 90 min 120 min 150 min 180 min 
ME 200 56.0 ± 1.64 85.8 ± 2.67 
(53.21) 
97.4 ± 4.33 
(73.93) 
58.4 ± 0.51 
(4.29) 
54.4 ± 2.37 
(2.86) 
50.2 ± 2.0 
(10.36) 
47.8 ± 2.31a 
(14.64) 
  400 67.6 ± 1.81 69.2 ± 2.67 
(2.37) 
76.2 ± 2.35 
(12.72) 
67.2 ± 2.56 
(0.59) 
61.6 ± 1.72 
(8.88) 
56.2 ± 3.7 a 
(16.86) 




0.2 61.8 ± 2.0 68.8 ± 1.46 
(11.33) 
86.6 ± 1.72 
(40.13) 
66.2 ± 1.5 
(7.12) 
62.0 ± 2.26 
(3.24) 
61.8 ± 2.27 
(0.0) 
60.6 ± 2.42 
(1.94) 
Control - 61.6 ± 2.73 80.4 ± 2.91 
(30.52) 
111.0 ± 5.2 
(80.19) 
93.8 ± 3.82 
(52.27) 
66.2 ± 2.27 
(7.47) 
63.4 ± 2.38 
(2.92) 
61.6 ± 2.84 
(0.0) 
 
n = 5; aP<0.05 compared to zero minute values (ANOVA; LSD post hoc); ME = methanol extract; EF = ethyl acetate fraction; MF = methanol 
fraction. 














Day 14 Day 28 
ME 200 58.6 ± 2.62 414.2 ± 60.43 241.2 ± 20.32* (41.77) 193.7 ± 31.5*  (53.24) 
  400 63.6 ± 7.76 324.0 ± 55.04 111.3 ± 10.35* (65.74) 107.7 ± 8.13* (66.76) 
NDT 200 52.2 ± 0.97 56.6 ± 1.50 75.4 ± 7.98* 93.0 ± 6.43* 
NDNT - 55.6 ± 2.69 55.6 ± 2.87 76.8 ± 4.04* 97.0 ± 5.79* 
Glibenclamide 0.2 62.4 ± 2.79 499.0 ± 15.57 235.8 ± 17.96* (52.75) 187.2 ± 3.17*  (62.48) 
 
n = 5; *P<0.05 compared to Diabetic Pre-treatment values (ANOVA; LSD post hoc); ME = Methanol extract; NDNT = Non-diabetic 
non-treated was a non-diabetic control and received the vehicle; NDT = Non-diabetic treated was a non-diabetic control and 
received ME (200 mg/kg). 
Values in parenthesis represent reduction (%) of blood glucose calculated for treatment groups relative to Diabetic Pre-treatment 




glibenclamide-treated and control rats (Table 3). 
 
 
Effect of ME on blood glucose of diabetic rats 
 
Chronic oral administration of ME caused a significant 
(P<0.05) dose-related reduction in blood glucose levels 
of diabetic, but not normoglycaemic rats. The extract re-
duced blood glucose of treated rats better than 
glibenclamide (Table 4) and prolonged the survival of 
diabetic rats beyond the period of the study. All the 
animals in the non-treated diabetic control group died by 
day 10 post induction of diabetes (data not shown). 
 
 
Effect of ME on total cholesterol and triglyceride 
levels of diabetic rats  
 
Chronic administration of ME reduced total cholesterol 
and triglycerides levels of diabetic rats. The ME caused 
a significant (P<0.05) dose-related reduction in total 
cholesterol of treated diabetic and normoglycaemic rats 
(Table 5). Also, ME significantly (P<0.05) reduced serum 
triglyceride level of diabetic and normoglycaemic rats in 
a dose-related manner. The magnitude of reduction was 
greater in diabetic than normoglycaemic rats and also 
higher than that evoked by glibenclamide (Table 6).  
 
 
Effect of ME on haemoglobin levels and cell counts 
of diabetic rats 
 
The haemoglobin (Hb) levels of all the animals was sig-
nificantly (P<0.05) reduced initially on day 14. Subse-
quently, on day 28, ME-treated diabetic rats had slight 
increase in Hb levels while the reduction continued in the 
non-extract treated groups (Table 7). The extract (ME) 
caused a similar effect on red blood cell (RBC) counts of 
diabetic rats except that the RBC counts of gliben-
clamide-treated rats increased from day 14 (Table 8). On 
white blood cells (WBC) counts, ME increased cell 
counts of  diabetic  and  normoglycaemic  rats.  Also  the  














Day 14 Day 28 
ME 200 121.5 ± 5.3 180.7 ± 3.1 85.4 ± 35.1b (52.74) 84.9 ± 34.9b (53.02) 
  400 120.0 ± 1.4 148.7 ± 4.8 70.0 ± 29.5b (52.93) 67.6 ± 28.5b (54.54) 
NDT 200 128.6 ± 7.4 121.8 ± 3.2 103.8 ± 3.2a,b (14.78) 103.5 ± 3.9a,b (15.02) 
NDNT - 122.3 ± 5.8 123.0 ± 5.8 124.6 ± 5.3 (-1.30) 124.6 ± 5.2 (-1.30) 
Glibenclamide 0.2 129.8 ± 20.8 152.6 ± 2.6 165.1 ± 2.4b (-8.19) 156.5 ± 2.0 (-2.56) 
 
n = 5; a,bP<0.05 compared to Basal and Diabetic Pre-treatment values respectively (ANOVA; LSD post hoc); ME = Methanol 
extract; NDNT = Non-diabetic non-treated was a non-diabetic control and received the vehicle; NDT = Non-diabetic treated 
was a non-diabetic control and received ME (200 mg/kg). 
Values in parenthesis represent reduction (%) of total cholesterol calculated for treatment groups relative to Diabetic Pre-















Day 14 Day 28 
ME 200 116.36 ± 5.30 165.56 ± 6.50 142.42 ±10.10 (13.98) 141.44 ± 9.67 (14.57) 
  400 114.53 ± 7.53 148.59 ± 7.64 107.57 ± 1.66a (27.61) 105.65 ± 2.15a (28.90) 
NDT 200 93.80 ± 4.36 89.96 ± 3.46 78.79 ± 2.21a (12.42) 78.85 ± 2.03a (12.35) 
NDNT - 104.55 ± 2.03 105.23 ± 1.73 108.18 ± 5.5 (-2.80) 109.38 ± 4.92 (-3.94) 
Glibenclamide 0.2 90.47 ± 0.94 120.46 ± 4.21 112.0 ± 1.70a (7.02) 99.72 ± 1.26a (17.22) 
 
n = 5; aP<0.05 compared to Diabetic Pre-treatment (ANOVA; LSD post hoc); ME = Methanol extract; NDNT = Non-diabetic non-
treated was a non-diabetic control and received the vehicle; NDT = Non-diabetic treated was a non-diabetic control and received 
ME (200 mg/kg). 
















Day 14 Day 28 
ME 200 16.07 ± 0.06 15.56 ± 0.25 13.55 ± 0.24a,b 13.78 ± 0.21a,b 
  400 15.94 ± 0.16 15.71 ± 0.19 13.74 ± 0.05a,b 13.90 ± 0.08a,b 
NDT 200 16.13 ± 0.05 15.96 ± 0.03 14.80 ± 0.28a,b 14.70 ± 0.23a,b 
NDNT - 15.75 ± 0.26 15.65 ± 0.31 13.98 ± 0.23a,b 13.56 ± 0.11a,b 
Glibenclamide 0.2 14.08 ± 0.08 14.03 ± 0.07 13.82 ± 0.07a 13.66 ± 0.07a,b 
 
n = 5; a,bP<0.05 compared to Basal and Diabetic pre-treatment values respectively (ANOVA; LSD post hoc); ME 
= methanol extract; NDT = Non-diabetic treated was a non-diabetic control and received ME (200 mg/kg); 




WBC counts of the non-diabetic non-treated control as 
well as glibenclamide-treated groups were increased by 
day 28 (Table 9). 
Effect of ME on body weight of treated diabetic rats 
 
There was a significant  (P<0.05)  increase  in  the  body  














Day 14 Day 28 
ME 200 5.19 ± 0.09 5.11 ± 0.09 4.83 ± 0.04 5.50 ± 0.09 
  400 4.98 ± 0.10 4.87 ± 0.09 4.69 ± 0.05 4.95 ± 0.08 
NDT 200 5.24 ± 0.09 5.15 ± 0.10 4.90 ± 0.12 4.81 ± 0.11 
NDNT - 5.07 ± 0.19 4.92 ± 0.16 4.65 ± 0.15 6.51 ± 0.12 
Glibenclamide 0.2 5.37 ± 0.05 5.29 ± 0.08 4.66 ± 0.19 5.51 ± 0.06 
 
n = 5; ME = methanol extract; NDT = Non-diabetic treated was a non-diabetic control and received ME 














Day 14 Day 28 
ME 200 4.66 ± 0.09 4.58 ± 0.04 4.73 ± 0.12 4.84 ± 0.07 
  400 4.86 ± 0.16 4.78 ± 0.14 4.95 ± 0.11 5.12 ± 0.10 
NDT 200 4.83 ± 0.12 4.75 ± 0.15 4.47 ± 0.13 4.75 ± 0.14 
NDNT - 4.52 ± 0.05 4.39 ± 0.61 4.26 ± 0.07 5.46 ± 0.11 
Glibenclamide 0.2 4.71 ± 0.08 4.73 ± 0.08 4.60 ± 0.07 4.66 ± 0.06 
 
n = 5; ME = methanol extract; NDT = Non-diabetic treated was a non-diabetic control and received ME 














Day 14 Day 28 
ME 200 126.0 ± 1.87 120.6 ± 5.42 136.7 ± 11.11 (13.34) 139.0 ± 11.62 (15.26) 
  400 120.0 ± 5.24 120.0 ± 5.24 160.0 ± 5.5a (33.33) 161.0 ± 12.27a (34.17) 
NDT 200 124.0 ± 8.28 123.6 ± 8.57 181.6 ± 11.51a (46.93) 184.0 ± 10.34a (48.87) 
NDNT - 121.0 ± 5.57 121.0 ± 5.57 201.0 ± 12.69a (66.12) 202.6 ± 13.31a (67.44) 
Glibenclamide 0.2 274.8 ± 6.97 273.0 ± 7.40 271.0 ± 7.84 (NI) 275.0 ± 6.38 (0.73) 
 
n = 5; aP<0.05 compared to Diabetic Pre-treatment (ANOVA; LSD post hoc); ME = Methanol extract; NDNT = Non-diabetic non-
treated was a non-diabetic control and received the vehicle; NDT = Non-diabetic treated was a non-diabetic control and received 
ME (200 mg/kg). 
Values in parenthesis represent increase (%) in body weight calculated for treatment groups relative to Diabetic Pre-treatment 




weights of treated diabetic, non-treated non-diabetic and 
normoglycaemic animals. The weight increase occurred 
most in the non-diabetic non-treated group followed by 
non-diabetic treated rats. The ME-treated rats had 
modest increase in body weight while glibenclamide-
treated rats had little or no remarkable change in weight 
(Table 10). 
Effect of ME on pancreatic tissues of diabetic rats 
 
Histopathological studies showed that no necrosis was 
seen in the non-diabetic non-treated group. The non-
diabetic non-treated group did not show any microscopic 
lesion around the islet tissues and the alveolar cells 

















necrosis of the islet tissues with the alveolar cells mode-
rately destroyed (Figure 2). In ME-treated animals, the 
architecture of the pancreas appeared intact. The 
characteristic interlobular and intralobular ducts as well 
as the alveolar granules were seen (Figures 3, 4 and 5). 
The glibenclamide treated group showed evidence of 
destruction of  the  alveolar  cells  with  severe  necrosis 





DM has a significant impact on the health, quality of life 
and life expectancy of patients as well as healthcare 
expenditure. With increasing incidence and mortality 
from its complications, prompt and adequate glycaemic 
control in diabetes is paramount if management can 
meaningfully improve the quality of life and increase life 
expectancy. In this study, experimental evaluation of the 
anti-diabetic potentials of P. niruri has shown that single 
oral administration of the extract to normal rats reduced 
fasting blood glucose which suggests an inherent 
hypoglycaemic effect. The extract also suppressed the 
postprandial   rise   in   blood   glucose   in   normal   rats  












Figure 4. Effect of ME (200 mg/kg) on pancreatic tissue of alloxan-




following a heavy glucose meal with maximum suppres-
sive effect coinciding with the time of peak blood glucose 
level after the meal. The time-course of events also 
showed that the extract reduced glucose level to below 
basal in less than 2 h compared to the 2.5 h for gliben-
clamide to achieve a return to basal levels. Chronic 
hyperglycaemia in DM is a risk factor constantly fuelled 
by postprandial elevation of blood glucose. Control of 
postprandial hyperglycaemia in diabetes is of great 
importance due to its close relation to the risk of micro 
and macro-vascular complications and death (Balkau, 
2000; Ceriello, 2005). Interestingly, in addition to hypo-
glycaemic effect, the extract may also suppress post-
prandial rise in blood glucose levels both of which are 
indices of effective glycaemic control.  
In the anti-diabetic activity studies, daily oral adminis-
tration of the extract for 28 days produced a gradual but 
sustained reduction in blood glucose levels in diabetic 
rats. Alloxan causes hyperglycaemia and glucose intole-
rance or syndromes similar to either type 1 or type 2 DM 
(Lenzen et al., 1996; Frode and  Medeiros, 2008).  Effec-  






Figure 5. Effect of ME (400 mg/kg) on pancreatic tissue of alloxan-




tive and sustained reduction in blood glucose levels of 
treated diabetic rats by the extract indicates that it may 
be useful in overt cases of DM. Treatment with the ex-
tract also reduced mortality of diabetic rats from hyper-
glycaemia and prolonged their survival. In this study, the 
diabetic non-treated control animals all died on day 10 
post-induction of diabetes (data not shown) whereas the 
extract-treated group survived beyond the period of the 
experiment. Effective control of blood glucose level is a 
key step in preventing and reversing diabetic compli-
cations, and improving the quality of life of diabetic 
patients (The DCCT, 1993; Bavarva and 
Narasimhacharya, 2008). Hence, chronic administration 
of the extract may cause a progressively sustained 
reduction in hyperglycaemia known to reduce the risk of 
complications associated with the disease. Chronic oral 
administration of the extract also reduced total choles-
terol and triglyceride levels in diabetic and normo-
glycaemic rats consistent with the hypolipidemic effect 
earlier reported (Khanna et al., 2002). Diabetic dysli-
pidaemia is marked by elevated triglycerides, cholesterol 
and low density lipoprotein (LDL) particles of altered 
composition and decreased high density lipoprotein 
(HDL), and constitutes an important cardiovascular risk 
factor in diabetics (Agrawal et al., 2006). Reduction in 
total cholesterol and triglycerides through dietary or drug 
therapy has been found beneficial in preventing diabetic 
complications as well as improving lipid metabolism in 
diabetic patients (Brown et al., 1993; Ahmed et al., 
2001). Experimentally, alloxan-induced diabetic hyper-
glycaemia is accompanied by increase in serum choles-
terol and triglyceride levels (Choi et al., 1991; Platel et 
al., 1993; Sharma et al., 1997; Rao et al., 1999; Prince 
et al., 1999; Ahmed et al., 2001) and mimics overt 
diabetes disease. Thus, in addition to glycaemic control, 
extract of this plant may further reduce mortality from 
complications of the disease by ameliorating diabetes-







Figure 6. Effect of glibenclamide on pancreatic tissue of alloxan-




Due to the association of obesity with DM, weight control 
is an important aspect of diabetes management. Poor 
glycaemic control usually results in weight loss. Our 
results showed that all the animals used gained weight 
during the study. The weight gain was highest in the 
nondiabetic treated control while glibenclamide-treated 
control had almost none. We had thought that this could 
mean that the extract could cause weight increase in 
treated diabetic animals. However, on a closer look at 
the body weights of these animals, it was evident that 
whereas animals in the glibenclamide group were 
mature adult rats, those in other groups were young 
adult rats in their active growth stage. As such, the 
increase in their body weights throughout the study 
period was likely due to ongoing natural growth process. 
Although adequate glycaemic control by some agents 
may lead to increase in body weight such as that ob-
served with the thiazolidinediones (Monnier et al., 2003; 
Bhat et al., 2007), our current data is insufficient to draw 
any such conclusion with respect to the extract. That 
notwithstanding, it is important that chronic adminis-
tration of the extract did not inhibit the natural growth 
process of these animals with or without diabetes. It is 
doubtful if extract of aerial parts of this plant may offer 
any additional benefit to obese diabetics in dire need of 
weight reduction therapy as adjunct to glycaemic control. 
Assessment of the effect of chronic administration of 
the extract on Hb level as well as WBC and RBC counts 
revealed a slight increase following an initial reduction. It 
is not clear if this increase would progress to a return to 
basal levels and how long it may take. The extent of 
reduction in these parameters, however, did not appear 
to have posed any threat to the wellbeing and survival of 
treated animals.  
Several factors such as oxidative stress (Hayden et 
al., 2005), chronic hyperglycemia (Leung and Leung, 
2008) and autoimmune (Yoshida et al., 1995; Tanaka et 
al., 2000; Tanaka et al., 2001) or fibrocalculous (Mohan 





pancreas and impair insulin secretion and hence glyca-
emic control. Result of histological studies on pancreas 
isolated from treated diabetic rats showed that the 
extract may have repaired the pancreas damaged by 
alloxan. Alloxan owes its diabetogenic potential to 
destruction of -cells of the islet (Szudelski, 2001; Fröde 
and Medeiros, 2008) which consequently impairs insulin 
secretion and gives rise to hyperglycemia. Treatment 
with the extract may have restored the integrity and 
perhaps, functions of the damaged pancreatic tissues. 
Glibenclamide used as a reference hypoglycemic agent 
did not cause any such effect. The precise mechanism 
of this tissue repair is not known. However, due to the 
large implication of oxidative stress (Hayden et al., 2005; 
Leung and Leung, 2008) in damage to the pancreas, it 
seems reasonable to suggest that the antioxidant 
(Tasaduq et al., 2003) and radical scavenging (Jagetia 
and Baliga, 2004) effects of this plant may play a key 
role in protecting pancreatic tissues from oxidants 
including that generated by alloxan. Alloxan destroys 
insulin-producing pancreatic -cells through the 
formation of reactive oxygen species that cause tissue 
damage (Lee et al., 2008). The hypoglycaemic effect of 
the extract may further protect the pancreas from the 
deleterious effect of chronic hyperglycaemia. Rather 
than possessing a direct tissue repair effect, it is likely 
that the extract, through antioxidant and hypoglycaemic 
effects, protected the already compromised pancreas 
from further assault or tissue damage which then 
allowed the natural repair processes to proceed and 
restore the tissues. However, it is not clear if the 
repaired tissues also had their functions fully or partially 
restored since the blood glucose level of the animals did 
not return to basal or pre-treatment levels as at the end 
of the experiment. A return to basal or pre-treatment 
levels would have indicated full restoration of insulin 
secretion by the repaired pancreatic tissues.  
While the anti-diabetic effect of the extract may derive 
from its hypoglycaemic effect, the mechanisms of the 
hypoglycaemic effect are yet to be elucidated. The hypo-
glycaemic effect in normal and diabetic rats suggests an 
insulin-like effect probably mediated via peripheral glu-
cose consumption (De Sousa et al., 2004; Zanatta et al., 
2007). Also, postprandial hyperglycemia is related to 
postprandial hyperinsulinemia (Wang et al., 2004) and 
its suppression by the extract suggests an insulin-like 
effect. Phytochemical analysis of the extract revealed 
the presence of flavonoids, alkaloids, carbohydrates, 
glycosides and tannins which are typical plant consti-
tuents. Although there are chances that any of these 
constituents may possess anti-diabetic properties, 
extract of the whole plant may be more effective since 
the results of bioactivity-guided studies did not reveal 
any increase in magnitude of hypoglycaemic effect 
following solvent-guided fractionation. This observation 
precluded further fractionation of the extract in this study.  
It would thus  be  difficult  at  this  stage  to  attribute  the  









The results of this study showed that aerial parts of P. 
niruri have great potentials as antidiabetic remedy due to 
the ability of its extract to lower blood glucose and lipid 
levels in diabetic rats and suppress postprandial rise in 
blood glucose levels. These effects reduce the risk of 
complications associated with diabetes. It may addition-
ally protect the pancreas from further damage through 
antioxidant effect and effective glycaemic control. 
Chronic use may not cause any deleterious effect on 
haematological indices and body weight. The whole 
extract of the aerial parts may be more effective than the 
fractions although this does not preclude the isolation of 
hypoglycaemic constituents. Studies on the effect of the 
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